Alzheimer's disease affects many people and their families. This registry is gathering information about a type of medicine called **anti-amyloid monoclonal antibodies** (mAbs). These medicines help with Alzheimer's by targeting amyloid proteins that build up in the brain. The study will be managed by Georgia Memory Net, a program that helps diagnose Alzheimer's early and supports patients and families. The program has clinics around Georgia, where doctors will collect and compare data from people who use these new treatments with past patients who didn’t have access to them. This helps understand how well the medicines work and any potential side effects.

• Participants must be between 50-90 years old and meet specific health criteria.
• The registry involves clinic visits, tests like MRI, and having a care partner attend follow-ups.
• It's important to be aware of health conditions that may exclude you, like recent seizures or severe allergies.